ClinicalTrials.gg
Not yet recruitingNCT07940985Updated Nov 17, 2026

Effects of a Virtual Reality-Based Intervention in Older Adults With Cognitive Decline or Physical Frailty

An interventional study of Virtual Reality-Based Multidomain Intervention and Multidomain Health Education in Frailty and Cognitive Dysfunction, sponsored by Zheng Li. Not yet recruiting. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Zheng Li · Not applicable, Interventional, and Supportive care

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effects of a virtual reality intervention on cognitive and physical function in older adults with cognitive decline or physical frailty.

Read the detailed description

Cognitive and physical function are essential for maintaining independent living in older adults. This study aims to evaluate the effects of a virtual reality intervention on cognitive and physical function in older adults. Eligible older adults with cognitive decline, physical frailty, or both will be enrolled in a virtual reality intervention group or a control group. The intervention group will receive the virtual reality intervention specified in the study protocol, while the control group will receive the designated control intervention. Participants' cognitive function, physical function, and related health indicators will be assessed before the intervention and at the assessment time points specified in the study protocol. Changes over time will be compared between the two groups to evaluate the effects of the virtual reality intervention on cognitive and physical function. Intervention participation, completion, and withdrawal will be recorded, and intervention process measures will be collected to evaluate the feasibility and safety of the virtual reality intervention in older adults. This study will provide evidence to inform the use of virtual reality interventions to maintain and improve cognitive and physical function in older adults.

02

Conditions studied

  • Frailty
  • Cognitive Dysfunction

Keywords

  • Virtual Reality Intervention
  • Cognitive Function
  • Frailty
  • Community-dwelling Older Adults
03

In context

Frailty

1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 246 is above the median of 82 across 769 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Zheng Li is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60 years or older.
  • Presence of cognitive decline, physical frailty, or both.
  • Sufficient language comprehension and communication abilities to understand training instructions and complete study assessments.
  • Willingness to participate and provision of written .

Exclusion criteria

Exclusion Criteria:

  • A confirmed diagnosis of dementia or severe neurological or psychiatric disorders that interfere with training participation or outcome assessment.
  • Severe or unstable medical conditions that, in the judgment of the research team, make participation in training inappropriate.
  • Visual, hearing, or motor impairments that substantially interfere with equipment use, training participation, or completion of assessments despite correction or assistive devices.
  • A history of severe discomfort when using virtual reality equipment, or intolerable discomfort during equipment familiarization.
  • Current participation in another interventional study that may affect cognitive or physical function outcomes in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    Virtual Reality Intervention

    Virtual reality intervention integrating cognitive training, physical exercise, nutrition education, and emotional support.

    Behavioral: Virtual Reality-Based Multidomain Intervention

  • Active comparator
    Multidomain Health Education

    Multidomain health education

    Behavioral: Multidomain Health Education

Interventions

  • BehavioralVirtual Reality-Based Multidomain Intervention

    Participants will receive a virtual reality intervention integrating cognitive training, physical exercise, nutrition education, and emotional support. Sessions will be delivered twice weekly for 24 weeks, for a total of 48 sessions. Each session will last approximately 40 minutes including instructions, warm-up activities, structured training, and breaks as needed. Participants will receive guidance to familiarize themselves with the virtual reality equipment before commencing structured training.

  • BehavioralMultidomain Health Education

    Participants will receive multidomain health education covering cognitive health, physical activity, nutrition guidance, and emotional well-being.

06

What researchers measure

Primary outcomes

  1. Subjective Cognitive Decline

    Subjective cognitive decline will be assessed using the nine-item Subjective Cognitive Decline Questionnaire (SCD-Q9). Total scores range from 0 to 9, with higher scores indicating greater subjective cognitive decline. Changes from baseline will be evaluated at each follow-up assessment.

    Time frame: Baseline, Week 8, Week 16, and Week 24

  2. Objective Cognitive Function

    Objective cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). Total scores range from 0 to 30, with higher scores indicating better cognitive function. Changes from baseline will be evaluated at each follow-up assessment.

    Time frame: Baseline, Week 8, Week 16, and Week 24

  3. Frailty

    Frailty will be assessed using the Fried Frailty Phenotype (FFP), which includes five components including unintentional weight loss, slow walking speed, low grip strength, low physical activity, and exhaustion. Total scores range from 0 to 5, with higher scores indicating greater physical frailty.

    Time frame: Baseline, Week 8, Week 16, and Week 24

Secondary outcomes

  1. Depressive Symptoms

    Depressive symptoms will be assessed using the nine-item Patient Health Questionnaire (PHQ-9). Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline, Week 8, Week 16, and Week 24

  2. Anxiety Symptoms

    Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7) scale. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

    Time frame: Baseline, Week 8, Week 16, and Week 24

  3. Apathy

    Apathy will be assessed using the three-item apathy subscale of the Geriatric Depression Scale (GDS-3A). Total scores range from 0 to 3, with higher scores indicating greater apathy.

    Time frame: Baseline, Week 8, Week 16, and Week 24

  4. Economic-related Evaluation

    Health-related quality of life will be assessed with the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L). The health utility index will be calculated using the Chinese value set.

    Time frame: Baseline and Week 24 (end of the intervention)

  5. Satisfaction and Acceptability of Virtual Reality Technology

    Satisfaction and acceptability of virtual reality technology will be assessed using the questionnaire on older adults' acceptance of immersive virtual reality experiences, covering perceived usefulness, perceived ease of use, perceived enjoyment, user experience, and intention to use.

    Time frame: At the end of the intervention (Week 24)

  6. Engagement

    Engagement will be assessed using the participant intervention process record questionnaire, and higher frequency and longer duration of participation indicate better engagement.

    Time frame: Throughout the intervention period, 24 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 11 months is below that.

Counting every sponsor, half of 518 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940985
Lead sponsor
Zheng Li
Responsible party
Zheng Li (Professor, Peking Union Medical College) — Sponsor-investigator
First posted
Nov 17, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Zheng Li
Contact
zhengli@pumc.edu.cn
010-88771006

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion